MX2022005676A - Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos. - Google Patents

Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos.

Info

Publication number
MX2022005676A
MX2022005676A MX2022005676A MX2022005676A MX2022005676A MX 2022005676 A MX2022005676 A MX 2022005676A MX 2022005676 A MX2022005676 A MX 2022005676A MX 2022005676 A MX2022005676 A MX 2022005676A MX 2022005676 A MX2022005676 A MX 2022005676A
Authority
MX
Mexico
Prior art keywords
methods
polypeptides
making
releasable
barcoded
Prior art date
Application number
MX2022005676A
Other languages
English (en)
Inventor
Volker Schellenberger
Eric Johansen
Angela Henkensiefken
Original Assignee
Amunix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Pharmaceuticals Inc filed Critical Amunix Pharmaceuticals Inc
Publication of MX2022005676A publication Critical patent/MX2022005676A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

En la presente descripción se describen polipéptidos que comprenden un polipéptido recombinante extendido (XTEN) compuesto por una pluralidad de motivos de secuencia superpuestos y uno o más fragmentos de código de barras liberables tras la digestión con proteasa y detectables a partir de todos los demás fragmentos liberables proteolíticamente. Ciertas modalidades de estos polipéptidos comprenden además un polipéptido biológicamente activo, en donde modalidades ventajosas de este comprenden un segmento liberable capaz de escisión proteolítica que escinde el enlace entre el polipéptido XTEN y el polipéptido biológicamente activo. También se describen métodos de preparación y métodos de uso de dichos polipéptidos.
MX2022005676A 2019-11-13 2020-11-13 Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos. MX2022005676A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962934980P 2019-11-13 2019-11-13
PCT/US2020/060378 WO2021097186A1 (en) 2019-11-13 2020-11-13 Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Publications (1)

Publication Number Publication Date
MX2022005676A true MX2022005676A (es) 2022-10-27

Family

ID=73740585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005676A MX2022005676A (es) 2019-11-13 2020-11-13 Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos.

Country Status (12)

Country Link
US (1) US20230287040A1 (es)
EP (1) EP4058466A1 (es)
JP (1) JP2023501478A (es)
KR (1) KR20220131221A (es)
CN (1) CN115175920A (es)
AU (1) AU2020382621A1 (es)
BR (1) BR112022009217A2 (es)
CA (1) CA3157605A1 (es)
CO (1) CO2022008004A2 (es)
IL (1) IL292863A (es)
MX (1) MX2022005676A (es)
WO (1) WO2021097186A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537824A (ja) * 2019-06-26 2022-08-30 アムニクス ファーマシューティカルズ， インコーポレイテッド Ｃｄ３抗原結合断片およびそれを含む組成物
KR20230041711A (ko) * 2020-06-25 2023-03-24 아뮤닉스 파마슈티컬스, 인크. Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법
WO2023092099A1 (en) * 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3484377D1 (de) 1983-06-15 1991-05-08 Celltech Ltd Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
DK27885A (da) 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
ATE105868T1 (de) 1985-09-12 1994-06-15 Scios Nova Inc Rekombinanter fibroblast-wachstumsfaktor.
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5631230A (en) 1989-09-21 1997-05-20 Arizona Technology Development Corporation Receptor selective analogues of cholecystokinin-8
US5364840A (en) 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
WO1992004363A1 (en) 1990-09-04 1992-03-19 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
JPH08510205A (ja) 1993-03-29 1996-10-29 ユニバーシティ オブ シンシナティ Ｙｙペプチドのアナログとその用途
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US6214797B1 (en) 1995-06-13 2001-04-10 The Salk Institute For Biological Studies Urocortin peptides, nucleic acid encoding same methods for using same
EP0845036B1 (en) 1995-08-18 1999-06-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
AU772069B2 (en) * 1999-03-23 2004-04-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Protein isolation and analysis
EP1197496B8 (en) 1999-07-23 2007-10-03 Kenji Kangawa Novel peptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
JP4237375B2 (ja) 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7419949B2 (en) 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
WO2004048547A2 (en) 2002-11-26 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Intermedin and its uses
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
EP1603935A4 (en) 2003-03-03 2007-03-21 Dyax Corp SPECIFIC TO HGF RECEPTOR (cMET) BINDING PEPTIDES AND THEIR USE
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
KR102274003B1 (ko) 2007-01-19 2021-07-08 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
BRPI0919840B1 (pt) 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
ES2705249T3 (es) 2009-06-08 2019-03-22 Amunix Operating Inc Polipéptidos reguladores de glucosa y métodos para su producción y uso
CN103140236B (zh) 2009-06-08 2017-04-19 阿穆尼克斯运营公司 生长激素多肽及其制备和使用方法
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
PL2882450T3 (pl) 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
KR20170083095A (ko) * 2014-11-11 2017-07-17 아뮤닉스 오퍼레이팅 인코포레이티드 표적화된 xten 접합체 조성물 및 이의 제조 방법
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure
JP6558679B2 (ja) 2015-04-24 2019-08-14 パナソニックＩｐマネジメント株式会社 点灯装置、照明装置及び照明器具
US11339434B2 (en) * 2016-07-29 2022-05-24 The Regents Of The University Of California Methods for determining gene functions
EP3728326A4 (en) * 2017-12-21 2021-12-15 Amunix Pharmaceuticals, Inc. RELEASE SEGMENTS AND LIAISON COMPOSITIONS INCLUDING THEM

Also Published As

Publication number Publication date
BR112022009217A2 (pt) 2022-08-02
WO2021097186A1 (en) 2021-05-20
US20230287040A1 (en) 2023-09-14
CA3157605A1 (en) 2021-05-20
KR20220131221A (ko) 2022-09-27
AU2020382621A1 (en) 2022-06-02
CN115175920A (zh) 2022-10-11
JP2023501478A (ja) 2023-01-18
IL292863A (en) 2022-07-01
EP4058466A1 (en) 2022-09-21
CO2022008004A2 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
MX2022005676A (es) Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos.
EP4321530A3 (en) Masked cytokine polypeptides
MX2021003261A (es) Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno.
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
ATE350470T1 (de) Durch thrombin spaltbare chimäre proteine
MX2023001595A (es) Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas.
DE602005026855D1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
AR118443A1 (es) Proteínas de fusión, bacterias recombinantes y fragmentos de exosporas para control de plagas y salud de las plantas
MX2022014167A (es) Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada.
PH12021550789A1 (en) Disulfide bond stabilized polypeptide compositions and methods of use
MX2022014162A (es) Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
CR20230178A (es) Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
MX2020005670A (es) Variantes de expresión de cdkl5 y proteínas de fusión de cdkl5.
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
MX2022008073A (es) Anticuerpos dirigidos a los huesos.
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
WO2006071250A3 (en) Soluble fragments of the sars-cov spike glycoprotein
PE20180162A1 (es) Polipeptidos dirigidos a la fusion de vih
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
ATE323763T1 (de) Dna & protein bindende miniatur proteine
AR116876A1 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
DE60313743D1 (de) Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen
MX2009009370A (es) Conjugados del complemento de peptido.
WO2019046446A3 (en) COMPOSITIONS AND METHODS USING METHANOTROPHE LAYER PROTEINS FOR THE EXPRESSION OF HETEROLOGOUS PROTEINS
AU2019365654A8 (en) Cleavable activators of CXCR3 and methods of use